A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07226427.

Trial PhasePhase I

Trial Typetreatment

Lead OrganizationStemline Therapeutics Inc

• Primary IDMEN2501-01
• Secondary IDsNCI-2026-00272
• ClinicalTrials.gov IDNCT07226427